Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care
- 1 January 1999
- journal article
- research article
- Published by Springer Science and Business Media LLC in PharmacoEconomics
- Vol. 16 (5), 459-472
- https://doi.org/10.2165/00019053-199916050-00004
Abstract
Objective: To measure the cost effectiveness of a supportive care intervention when the no-treatment option is unrealistic in an analysis of recombinant human erythropoietin (epoetin) treatment for anaemic patients with cancer undergoing chemotherapy. Further, to assess whether quality-adjusted life-years (QALYs) can provide the basis for an appropriate measure of the value of supportive care interventions. Design: A modelling study drawing cost and effectiveness assumptions from a literature review and from 3 US clinical trials involving more than 4500 patients with cancerwhowere treatedwith chemotherapy, radiotherapy, epoetin and blood transfusions as needed under standard care for patients with cancer. Main outcome measures and results: When compared with transfusions, epoetin is cost effective under varying assumptions, whether effectiveness is measured by haemoglobin level or quality of life. Specifically, under a base-case scenario, the effectiveness resulting from $US1 spent on standard care can be achieved with only $US0.81 of epoetin care. Due in part to the health-state dependence of the significance patients attach to incremental changes in their responses on the linear analogue scale, cost per QALY results are ambiguous in this supportive care context. Conclusions: Under a broad range of plausible assumptions, epoetin can be used cost effectively in the treatment of anaemic patients with cancer. Further, QALYs have limited applicability here because, as a short term supportive treatment, epoetin enhances the quality but not the length of life. Future research would benefit from the establishment of consistent values for quality-of-life changes across patients and health status, and the extension of the QALY framework to supportive care.Keywords
This publication has 17 references indexed in Scilit:
- What are cancer patients willing to pay for prophylactic epoetin alfa?Cancer, 1998
- The application of sample selection models to outcomes research: the case of evaluating the effects of antidepressant therapy on resource utilizationStatistics in Medicine, 1998
- Comment: Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced AnemiaAnnals of Pharmacotherapy, 1997
- Pharmacoeconomics: State of the Art in 1997Annual Review of Public Health, 1997
- Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.Journal of Clinical Oncology, 1997
- Accounting for future costs in medical cost-effectiveness analysisJournal of Health Economics, 1997
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997
- Cost Comparison of Recombinant Human Erythropoietin and Blood Transfusion in Cancer Chemotherapy-Induced AnemiaAnnals of Pharmacotherapy, 1997
- Transfusion requirements, risks, and costs for patients with malignancyTransfusion, 1995
- Healthy-years Equivalents versus Quality-adjusted Life YearsMedical Decision Making, 1993